olivLaw · US equity research
Verastem Oncology VSTM
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Verastem Oncology is a biopharmaceutical company in Boston focused on cancers driven by the RAS/MAPK pathway. It markets AVMAPKI FAKZYNJA CO-PACK, the first FDA-approved treatment for adults with KRAS-mutated recurrent LGSOC, while its VS-7375 KRAS G12D inhibitor is in clinical development. Net product revenue reached 30.9 million USD in the first seven months of the 2025 launch, while the net loss was 209.5 million USD in 2025, making financing and commercial execution central questions.
At the close of 04 Nov 2026, Verastem Oncology (VSTM) stock was 9.85 USD (+0.82% on the day), with market capitalisation 892.0 m USD, beta 1.22, 52-week range 3.45–10.64 USD. Latest reported quarter (Q2 2026): revenue of 40.1 m USD (+1,775.4% YoY), net income of -34.7 m USD, diluted EPS -0.35 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 61.9
- strong (55–70)
- Bollinger (20, 2)
- 7.54 – 10.82
- in the upper half of the band · %B 0.70 · band width 35.7%
- SMA 50 / 200
- 8.32 / 6.23
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.51 / 0.51
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +23.1% | −2.0% | +25.1 pp | — |
| 3 months | +67.8% | −2.2% | +70.0 pp | — |
| 6 months | +63.9% | +4.3% | +59.6 pp | — |
| Year to date | +27.6% | +10.6% | +17.0 pp | — |
| 1 year | +24.5% | +10.5% | +14.1 pp | +16.6% |
| 3 years | +43.8% | +73.7% | −29.9 pp | +16.8% |
| 5 years | −70.2% | +61.7% | −131.9 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 ≈ | 0 | — | 2.1 m | 11.2 m | 17.5 m | 18.7 m | 40.1 m |
| Research & development | 24.8 m | 20.8 m | 29.2 m | 24.8 m | 29.0 m | 31.7 m | 38.2 m | 41.3 m |
| SG&A | 12.3 m | 10.8 m | 15.0 m | 20.7 m | 21.0 m | 24.4 m | 22.3 m | 27.4 m |
| Operating income | -37.0 m | -31.6 m | -44.2 m | -43.8 m | -40.7 m | -41.5 m | -44.9 m | -32.7 m |
| Interest expense | 1.1 m | 1.1 m | 192.0 k | 212.0 k | 319.0 k | 415.0 k | 382.0 k | 360.0 k |
| Pre-tax income | — | — | — | -25.9 m | — | — | — | -33.9 m |
| Income tax | 0 | 185.0 k | 0 | 0 ≈ | 0 ≈ | — | 0 | 816.0 k |
| Net income | -24.0 m | -64.6 m | -52.1 m | -25.9 m | -98.5 m | -32.9 m | -36.6 m | -34.7 m |
| Diluted EPS | -0.60 | -1.33 ≈ | -0.96 | -0.62 | -1.35 | -0.39 ≈ | -0.46 | -0.35 |
| Operating cash flow | -23.8 m ≈ | -25.1 m | -38.7 m | -32.7 m ≈ | -36.2 m ≈ | -30.0 m | -52.1 m | -43.9 m ≈ |
| Capex | 0 ≈ | 0 | — | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | ⚠ 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.7 m | 17.5 m | 88.5 m | 2.1 m | 2.6 m | unavailable | 10.0 m | 30.9 m |
| Revenue YoY | unavailable | −34.7% | +407.1% | — | +26.4% | unavailable | unavailable | +209.1% |
| Net income | -72.4 m | -149.2 m | -67.7 m | -71.2 m | -73.8 m | -87.4 m | -130.6 m | -209.5 m |
| Net income YoY | unavailable | unavailable | unavailable | — | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -1.37 | -2.00 | -0.44 | -4.90 | -4.57 | -3.96 | -3.66 | -3.02 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | — | unavailable | unavailable | unavailable | unavailable |
| net % | -271.1% | -854.8% | -76.5% | -3,468.1% | -2,843.3% | unavailable | -1,306.4% | -677.6% |
| Free cash flow | -76.0 m | -138.5 m | -33.5 m | -53.7 m | unavailable | unavailable | -104.8 m | unavailable |
The series breaks before 2021: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 205.0 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 57.2 m USD
- Total assets
- 246.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 3.09x
- ROE
- unavailable
- ROA
- -120.4%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 88.5 m | 2.1 m | 2.6 m | — | 10.0 m | 30.9 m | SEC (XBRL)· 04 Mar 2026verified |
| Research & development | 41.4 m | 39.3 m | 50.6 m | 61.4 m | 81.3 m | 114.6 m | SEC (XBRL)· 04 Mar 2026verified |
| SG&A | 62.8 m | 24.1 m | 25.0 m | 30.7 m | 43.6 m | 81.1 m | SEC (XBRL)· 04 Mar 2026verified |
| Operating income | -49.4 m | -61.4 m | -72.9 m | -92.1 m | -115.0 m | -170.1 m | SEC (XBRL)· 04 Mar 2026verified |
| Interest expense | 15.8 m | 10.0 m | 2.1 m | 4.1 m | 4.6 m | 1.1 m | SEC (XBRL)· 04 Mar 2026verified |
| Pre-tax income | -67.5 m | -71.2 m | -73.8 m | -87.4 m | -130.5 m | -209.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Income tax | 194.0 k | 0 | 0 | — | 185.0 k | — | SEC (XBRL)· 20 Mar 2025verified |
| Net income | -67.7 m | -71.2 m | -73.8 m | -87.4 m | -130.6 m | -209.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Diluted EPS | -0.44 | -4.90 | -4.57 | -3.96 | -3.66 | -3.02 | SEC (XBRL)· 04 Mar 2026verified |
| Weighted average diluted shares | 153.3 k | 14.5 m | 16.1 m | 22.1 m | 35.7 m | 69.3 m | SEC (XBRL)· 04 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 67.8 m | 21.3 m | 74.9 m | 77.9 m | 88.8 m | 205.0 m | SEC (XBRL)· 04 Mar 2026verified |
| Inventories | — | — | — | — | — | 1.8 m | SEC (XBRL)· 04 Mar 2026verified |
| Current assets | 144.9 m | 105.7 m | 92.9 m | 143.7 m | 95.0 m | 223.4 m | SEC (XBRL)· 04 Mar 2026verified |
| Property, plant & equipment, net | 416.0 k | 210.0 k | 92.0 k | 37.0 k | 32.0 k | — | SEC (XBRL)· 20 Mar 2025verified |
| Intangibles (excl. goodwill) | — | — | — | — | — | 16.4 m | SEC (XBRL)· 04 Mar 2026verified |
| Total assets | 154.3 m | 108.7 m | 95.1 m | 149.7 m | 101.5 m | 246.4 m | SEC (XBRL)· 04 Mar 2026verified |
| Accounts payable | 1.9 m | 2.3 m | 4.9 m | 7.2 m | 4.0 m | 12.4 m | SEC (XBRL)· 04 Mar 2026verified |
| Long-term debt | — | — | 24.5 m | 40.1 m | 40.7 m | — | SEC (XBRL)· 20 Mar 2025verified |
| Current liabilities | 17.1 m | 18.6 m | 21.7 m | 26.4 m | 31.0 m | 72.3 m | SEC (XBRL)· 04 Mar 2026verified |
| Total liabilities | 39.1 m | 21.1 m | 47.7 m | 71.2 m | 130.4 m | 189.2 m | SEC (XBRL)· 04 Mar 2026verified |
| Equity | 115.3 m † | 87.6 m † | 47.4 m † | 57.4 m † | -28.9 m † | 57.2 m † | SEC (XBRL)· 04 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -33.5 m | -53.5 m | -63.7 m | -86.5 m | -104.8 m | -137.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Capex | 33.0 k | 196.0 k | — | — | 28.0 k | — | SEC (XBRL)· 20 Mar 2025verified |
| Free cash flow | -33.5 m ≈ | -53.7 m ≈ | — | — | -104.8 m ≈ | — | SEC (XBRL)· 20 Mar 2025derived |
| Investing cash flow | -47.4 m | 87.0 k | 66.2 m | -44.4 m | 60.0 m | -9.6 m | SEC (XBRL)· 04 Mar 2026verified |
| Financing cash flow | 69.6 m | 6.9 m | 51.8 m | 134.2 m | 54.8 m | 263.3 m | SEC (XBRL)· 04 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 892.0 m USD
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -231.6% | 21 (vs peers) | 25% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 128.4% | 100 (on a fixed band) | 33% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -108.3x | 0 (on a fixed band) | 25% |
| Current ratio · Balance sheet | 2.3x | 100 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial21/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Verastem, Inc. (VSTM). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 30.9 m USD in 2025; YoY growth 209.1%; net margin -231.6%; ROE -471.2%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 128.4%
- Current ratio: 2.3x
What contradicts it
- Net margin: -231.6%
- Interest coverage: -108.3x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,325.9 bn | 45.7 | 86.1% | 31.9% | +44.7% | +31% / +138% |
| JNJJohnson & Johnson | 640.8 bn | 40.4 | 20.0% | 16.2% | +6.0% | +29% / +72% |
| ONCBeone Medicines Ltd. | 524.7 bn | 817.5 | 14.7% | 10.7% | +40.2% | +4% / +90% |
| ABBVAbbVie Inc. | 505.5 bn | 49.2 | — | 15.7% | +8.6% | +26% / +101% |
| MRKMerck & Co., Inc. | 356.9 bn | 115.6 | 7.0% | 4.8% | +1.3% | +38% / +41% |
| ABTAbbott Laboratories | 190.6 bn | 30.6 | 12.4% | 13.9% | +5.7% | −15% / +5% |
| PFEPfizer Inc | 171.0 bn | 42.7 | 4.4% | 6.3% | −1.6% | +17% / −2% |
| VRTXVertex Pharmaceuticals Inc | 134.6 bn | 34.2 | 20.8% | 30.7% | +8.9% | +22% / +50% |
| BMYBristol-Myers Squibb Company | 126.1 bn | 13.7 | 44.1% | 18.5% | −0.2% | +25% / +25% |
| TEVATeva Pharmaceutical Industries Limited | 48.9 bn | 97.6 | 6.6% | 3.6% | +4.3% | +56% / +327% |
| ZTSZoetis Inc. | 34.3 bn | 13.7 | 64.4% | 27.5% | +2.3% | −35% / −53% |
| ROIVRoivant Sciences Ltd. | 26.0 bn | — | -6.2% | -3,535.0% | −71.6% | +73% / +277% |
| UTHRUnited Therapeutics Corporation | 25.8 bn | 21.5 | 19.3% | 41.6% | +10.6% | +24% / +151% |
| RPRXRoyalty Pharma plc | 25.8 bn | 37.6 | 8.5% | 32.1% | +5.1% | +66% / +145% |
| INSMInsmed Inc | 22.9 bn | — | -72.5% | -39.9% | +66.7% | −50% / +317% |
| VTRSViatris Inc. | 21.7 bn | — | -23.6% | -23.9% | −3.0% | +77% / +106% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.4 bn | 8.1 | 126.6% | 52.8% | +65.2% | −65% / −5% |
| TGTXTg Therapeutics, Inc. | 9.4 bn | 22.5 | 100.3% | 55.2% | +87.3% | +85% / +381% |
| BLRXBioLineRx Ltd | 4.9 bn | — | -12.8% | -171.7% | −95.9% | −46% / −97% |
| BHCBausch Health Companies Inc. | 3.1 bn | — | — | -7.6% | +6.7% | +31% / +17% |
| ANABAnaptysbio, Inc. | 1.4 bn | 11.5 | — | 82.4% | +157.0% | +71% / +404% |
| VSTMVerastem, Inc. | 892.0 m | — | -471.2% | -231.6% | +209.1% | +25% / +44% |
| KURAKura Oncology, Inc. | 677.0 m | — | -167.7% | -384.3% | +25.2% | −37% / −21% |
| DMACDiaMedica Therapeutics Inc. | 580.8 m | — | -114.6% | — | unavailable | +25% / +341% |
| PHATPhathom Pharmaceuticals, Inc. | 461.7 m | — | — | -30.2% | +216.9% | −64% / −19% |
1- and 3-year price returns: for VSTM from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Verastem Oncology is a biopharmaceutical company in Boston focused on cancers driven by the RAS/MAPK pathway. It markets AVMAPKI FAKZYNJA CO-PACK, the first FDA-approved treatment for adults with KRAS-mutated recurrent LGSOC, while its VS-7375 KRAS G12D inhibitor is in clinical development. Net product revenue reached 30.9 million USD in the first seven months of the 2025 launch 1, while the net loss was 209.5 million USD in 2025 1, making financing and commercial execution central questions.
SWOT
Strengths
- The company has an approved product and a commercial team already in place in the U.S., which shortens the path to revenue 1.
- VS-7375 holds Fast Track Designation for several indications and has encouraging early clinical data 23.
- The portfolio spans several signaling pathways, offering scientific diversification 1.
Weaknesses
Opportunities
Risks
- Dependence on a single producthigh
Commercial success of AVMAPKI FAKZYNJA depends on several factors, including physician and payer acceptance 1.
- Clinical trial failurehigh
Interim results may differ from final ones, and trials can fail at any stage 1.
- Need for additional financingmedium
The company has accumulated large losses and could need extra capital if sales do not grow enough 1.
- Conditional approvalmedium
Accelerated approval depends on confirmation of clinical benefit in a confirmatory trial 2.
- Leadership transitionlow
The CEO change announced for 2027 could affect the pace of execution 3.
Investment thesis
What would need to be true (bull case)
- If sales of AVMAPKI FAKZYNJA keep growing and RAMP 301 confirms benefit, the company could significantly expand its indication and sales 1.
- Favorable VS-7375 data could turn the candidate into a promising treatment for several KRAS G12D-mutated cancers 2.
- Commercial experience and an incoming CEO with oncology background could accelerate execution 3.
What would break the thesis
- If sales remain modest, the large losses could force the company to issue new equity or pursue other financing 1.
- The failure of a Phase 3 or Phase 2 trial could reduce portfolio value and delay future launches 1.
- Competition in the KRAS field and limited reimbursement could reduce the company's market share 1.
What to watch
- Rezultatele topline ale trialului RAMP 301mid-2027
- Topline results of the RAMP 301 trialmid-2027
- Trend of AVMAPKI FAKZYNJA sales over the first full quarters2027
- Initial data from the TARGET-D Phase 2 registration-directed trials2027
- Start of the new CEO's tenure and any strategic changesQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Verastem is a biopharmaceutical company developing and commercializing new medicines for patients with RAS/MAPK pathway-driven cancers 1. Its main commercial product is AVMAPKI FAKZYNJA CO-PACK, approved in the U.S. on May 8, 2025 under accelerated approval for adults with KRAS-mutated recurrent LGSOC who received prior systemic therapy 1. The portfolio also includes clinical, preclinical and early partnered programs, and the company notes that results from the RAMP 301 Phase 3 trial could support an expanded indication 1.
The strategy centers on inhibiting critical signaling nodes in cancer, including KRAS G12D directly, the RAF/MEK pathway downstream, and the parallel FAK pathway that drives resistance 1. The company says it has built a U.S. commercial presence that can be scaled for future launches 1. Stated priorities include sustaining the launch, advancing VS-7375 toward registration-directed studies, and prudent capital management 1.
In October 2026 the company announced a planned CEO transition, with a new President and CEO taking over effective January 1, 2027 3. The change comes as the company moves from launching its first product toward developing VS-7375 across several tumor types 3.
Segments
AVMAPKI FAKZYNJA CO-PACK
This is the only commercial product, for patients with KRAS-mutated recurrent LGSOC, approved under accelerated approval in the U.S. 1. The launch generated 30.9 million USD in net product revenue in the first seven months of 2025 1. The RAMP 301 study aims to confirm clinical benefit and expand the indication 2.
Market context
The addressable market is cancers driven by the RAS/MAPK pathway, where KRAS mutations are common 1. For LGSOC, the company estimates roughly 6,000 to 8,000 women in the U.S., with 1,000 to 2,000 new cases each year 1. The KRAS G12D opportunity is broader, especially in pancreatic, lung and colorectal cancer 2.
Market size depends on physician adoption and third-party payer coverage, factors the company treats as essential 1. If Phase 3 and registration-directed Phase 2 results prove favorable, the accessible market could grow significantly 1.
Trends
- Interest in KRAS inhibitorstailwind
Therapies targeting KRAS are an active field, and VS-7375 is among the candidates in this segment 2. If clinical data remain encouraging, the company could benefit from partner interest.
- Rising development costsheadwind
Research spending has increased from earlier years and may keep rising as trials grow larger 1. This could weigh on the net result in the coming periods.
- Payer and physician acceptancemixed
Adoption of AVMAPKI FAKZYNJA depends on payer coverage and physician views of safety 1. Favorable results could support sales growth, but reimbursement delays could slow it.
- Regulatory feedback and trial designmixed
FDA feedback led the company to separate its Phase 2 trials by cancer type 2. Regulatory shifts could change the development timeline.
Competitive position
The company notes that competing therapies could reduce its market share, and patients may enroll in competitors' trials 1. In KRAS G12C, Verastem discontinued its RAMP 203 study with Amgen, showing that the competitive landscape is evolving 1.
In pancreatic and lung cancer, several developers are working on KRAS inhibitors, and GenFleet is developing GFH375 in China 1. Verastem's position depends on the differentiation of VS-7375's ON/OFF profile and on comparative clinical results 2.
- GenFleet Therapeutics
The partner that develops VS-7375 as GFH375 in China and reports data from more than 150 patients 1.
- Amgen
A company Verastem collaborated with on RAMP 203, discontinued after interim data 1.
- Erasca
A partner for evaluating VS-7375 combined with a pan-RAS molecular glue, at the preclinical stage 2.
- AVEO Pharmaceuticals
An oncology company, now part of LG Chem, where the new CEO held senior roles earlier in his career 3.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancerSTAT News · 15 Oct 2026 · EN
SEC filings
- Current report14 Oct 2026Other events · Financial statements and exhibits
- Current report14 Oct 2026Results of operations · Departure or appointment of officers · Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report07 Aug 2026Material agreement · Creation of a direct financial obligation · Regulation FD disclosure · Financial statements and exhibits
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report23 Jun 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report17 Jun 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report26 May 2026Shareholder vote
- Current report07 May 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report07 May 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Verastem Oncology · 04 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Verastem Oncology · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Verastem Oncology · 14 Oct 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.